Comparing Bio-Techne (NASDAQ:TECH) & IB Acquisition (NASDAQ:IBAC)

Bio-Techne (NASDAQ:TECH) and IB Acquisition (NASDAQ:IBAC) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares Bio-Techne and IB Acquisition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
IB Acquisition	N/A	N/A	N/A

Institutional & Insider Ownership

99.0% of Bio-Techne shares are held by institutional investors. 1.3% of Bio-Techne shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Bio-Techne and IB Acquisition”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22 billion	9.33	$181.86 million	$1.15	62.88
IB Acquisition	N/A	N/A	N/A	N/A	N/A

Bio-Techne has higher revenue and earnings than IB Acquisition.

Analyst Ratings

This is a breakdown of recent recommendations for Bio-Techne and IB Acquisition, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0	15	2	0	2.12
IB Acquisition	1	0	0	0	1.00

Bio-Techne presently has a consensus target price of $68.92, indicating a potential downside of 4.69%. Given Bio-Techne’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Bio-Techne is more favorable than IB Acquisition.

Summary

Bio-Techne beats IB Acquisition on 9 of the 9 factors compared between the two stocks.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

About IB Acquisition

IB Acquisition Corp. is a blank check company. It formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses or entities. IB Acquisition Corp. is based in Boca Raton, Florida.